Kips Bay Medical Inc

Kips Bay Medical — Investor Presentation (April 2011)

27 slides from Kips Bay Medical's investor presentation, Apr 12, 2011

  1. Slide 1: eSVS MESH

    eSVS® MESH

  2. Slide 2: Disclaimer

    DISCLAIMER Certain statements and estimates in this presentation are “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are mainly based on our current expectations and estimates of future events and trends which affect o

  3. Slide 3: Manny Villafaña

    Co-Inventor of the first lithium pacemaker and Founder of CPI/Guidant Corporation Co-Inventor of the St. Jude heart valve and Founder of St. Jude Medical Inc. Co-Inventor the ATS heart valve and Founder of ATS Medical Co-Founder of the Lillehei Surgical Society Recipient “Living Legend of Medicine”

  4. Slide 4: Experienced Management Team

    EXPERIENCED MANAGEMENT TEAM Manny Villafaña – Founder, CEO and Chairman Founder, Chief Executive Officer and Chairman of the Board ATS Medical, Inc. Sold to Medtronic, Inc. for $370M Founder, Chief Executive Officer and Chairman of the Board St. Jude Medical, Inc. Current annual sales of approx. $5

  5. Slide 5: Coronary Artery Bypass Grafting (CABG)

    CORONARY ARTERY BYPASS GRAFTING (CABG) What is CABG? Coronary Artery Bypass Grafting involves the construction of an alternative path to bypass a narrowed or occluded coronary artery and restore blood flow from the aorta to an area past the occlusion. The advent of stents has decreased the use of CA

  6. Slide 6: Coronary Artery Bypass Grafts

    Internal Mammary Artery Saphenous Vein Synthetic Graft Implant Years CORONARY ARTERY BYPASS GRAFTS Vein Grafts Don’t Last as Long as Arterial Grafts 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

  7. Slide 7: eSVS MESH product design

    The eSVS MESH product is designed to give an implanted vein the physiological attributes of an artery by: Providing radial constriction (up to 35%), leading to arterial like flow characteristics within the graft Matching the typical compliance (~8%) of an artery KIPS BAY MEDICAL, INC. eSVS MESH

  8. Slide 8: CABG: Standard of Care for Multi-Vessel Disease

    CABG: STANDARD OF CARE FOR MULTI-VESSEL DISEASE January 2008 study compared drug-eluting stents with CABG in multi-vessel coronary disease New York study as Published in the New England Journal of Medicine Determined death rates and revascularization rates were higher in patients receiving drug-elut

  9. Slide 9: eSVS MESH in sheep aortocoronary vein grafts

    KIPS BAY MEDICAL, INC. eSVS MESH Newly implanted unsupported (bottom) and eSVS MESH supported (top) aortocoronary vein grafts in a sheep

  10. Slide 10: eSVS MESH Days - Sheep

    KIPS BAY eSVS MESH 30 DAYS - SHEEP Untreated venous graft – “control” (1) Venous graft treated w/ eSVS MESH (2)

  11. Slide 11: eSVS MESH Days - Sheep

    KIPS BAY eSVS MESH 30 DAYS - SHEEP Venous graft treated w/ eSVS MESH (4) Untreated venous graft – “control” (3)

  12. Slide 12: Sheep Gross Pathology / Histology

    180 DAYS SHEEP GROSS PATHOLOGY / HISTOLOGY Pre-clinical testing performed in large animal model Venous graft treated with eSVS MESH Untreated venous graft - “control”

  13. Slide 13: Clinical Studies and Data

    CLINICAL STUDIES AND DATA International Clinical Trial A study designed to support a European CE Mark application with enrollment from August 2008 to July 2009 7 centers enrolled 90 patients 85 patients (94%) reported results for the Primary Safety Endpoint (30-day MACCE) 73 patients (81%) reported

  14. Slide 14: Human Angiograms Months Post-Implant

    HUMAN ANGIOGRAMS 9 MONTHS POST-IMPLANT Untreated venous graft – “control” (5) Venous graft treated w/ eSVS MESH (6)

  15. Slide 15: Human Angiograms Months Post-Implant

    HUMAN ANGIOGRAMS 9 MONTHS POST-IMPLANT Untreated venous graft – “control” (7) Venous graft treated w/ eSVS MESH (8)

  16. Slide 16: Human Angiograms & Months Post-Implant

    HUMAN ANGIOGRAMS 9 & 24 MONTHS POST-IMPLANT Venous graft treated w/ eSVS MESH At 9 Months (9) Venous graft treated w/ eSVS MESH at 24 Months (10)

  17. Slide 17: Learnings from International Trial

    LEARNINGS FROM INTERNATIONAL TRIAL Device and implant procedure proven safe We recalibrated our sizing chart and discontinued the 3.0 millimeter eSVS MESH, our smallest sized device, as, in some cases, aggressive downsizing led to premature closure of the eSVS MESH treated venous grafts (we currentl

  18. Slide 18: Centers in Discussions for eSVS MESH Clinical Trial

    KIPS BAY IS IN DISCUSSIONS WITH THE FOLLOWING CENTERS TO PARTICIPATE IN eSVS MESH CLINICAL TRIAL Site Location Surgeons Cleveland Clinic Cleveland, Ohio Dr. Joseph Sabik Texas Heart Institute Houston, Texas Dr. Billy Cohn Emory University Atlanta, Georgia Dr. John Puskas Lenox Hill Hospital New York

  19. Slide 19: Proposed US Clinical Trial Design

    PROPOSED US CLINICAL TRIAL DESIGN Prospective, multi-center, randomized controlled trial (each patient receives both control and eSVS MESH treatments) Study to confirm the equivalent clinical safety and superior angiographic effectiveness At least 366 patients in two phases, feasibility rolling into

  20. Slide 20: Estimated Market US & Europe

    ESTIMATED MARKET US & EUROPE CABG Procedures: 448,000 US and 165,000 Europe annually with 3.3 Grafts per Procedure of which 2.3 Grafts per Procedure are Saphenous 1.4 Million Potential eSVS MESH Grafts Annually Current ASP @ $1,580 net per unit

  21. Slide 21: International Marketing Strategy

    INTERNATIONAL MARKETING STRATEGY Independent distributor model We require distributors to have an established client base in cardiac surgery Currently have 15 distributors covering 49 countries All contracts in US dollars Mr. Villafaña has established commercially successful independent distributor

  22. Slide 22: Intellectual Property

    INTELLECTUAL PROPERTY In 2007, Kips Bay Medical acquired the eSVS Mesh technology from Medtronic, Inc. for modest milestone and royalty payments 6 patent applications pending in the US Recent favorable decision from USPTO Board of Patent Appeals for our first eSVS MESH patent application The USPTO h

  23. Slide 23: Expected Milestones & US Clinical Pathway

    EXPECTED MILESTONES & US CLINICAL PATHWAY The FDA disapproved our most recent amendment to our application for an IDE. Follow-up conversations with the FDA have indicated that they need to review our IDE information with outside experts before they will provide further guidance to us. If we obtain t

  24. Slide 24: Capitalization Table – April 2, 2011

    CAPITALIZATION TABLE – APRIL 2, 2011 Debt --- 0.00% Common Stock Common shares, $0.01 par value (50M authorized) 15,734,291 88.73% Option Pool Option Shares Granted & Outstanding 943,000 5.32% Option Shares Available for Future Grants 1,056,000 5.95% Total Option Pool 1,999,000 11.27% Total Common a

  25. Slide 25: Investment Highlights

    INVESTMENT HIGHLIGHTS New medical technology in a company founded by Manny Villafaña Experienced management team with history of success Developing technology to address limitations in CABG surgery with potential for 1.4 million eSVS MESH grafts in the US and Europe annually Already approved and ini

  26. Slide 26: Thank you

    eSVS® MESH Thank you Not Available in the United States

  27. Slide 27: Descriptions of the Angiogram Videos Included in This Presentation

    DESCRIPTIONS OF THE ANGIOGRAM VIDEOS INCLUDED IN THIS PRESENTATION The foregoing presentation includes a series of embedded coronary angiogram videos. An angiogram is an X-ray test that uses a special dye and camera (fluoroscopy) to take pictures of the blood flow in an artery or a vein. During a co

Kips Bay Medical — Investor Presentation (April 2011) on 6ix